Compare ResMed Inc. (RMD) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs AT&T Inc. — how do they compare? ResMed Inc. trades at $228.86 (market cap $31.89B), while AT&T Inc. trades at $22.63 (market cap $170.42B). The key difference: AT&T Inc. is far larger — about 5.3× ResMed Inc.'s market cap, and AT&T Inc. pays the higher dividend (4.46%). Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and AT&T Inc. for 118 Days on average.
| RMD | T | |
|---|---|---|
Market Cap | $31.89B | $170.42B |
Volume | 618,314 | 50,780,036 |
Sector | Health | Media |
52-Week High | $277.88 | $29.10 |
52-Week Low | $182.82 | $20.49 |
Typical Hold Time | 51 Days | 118 Days |
Enterprise Value | $31.24B | $315.74B |
Dividend Yield | 1.16% | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical signal and strong fundamentals. Revenue grew to $5.15B in 2025, with net income at $1.40B and a 26.94% net margin. Recent earnings beats and a 12-14% EPS growth outlook support momentum. The stock is near its pivot point of $227, with support at $225 and resistance at $228.
Outlook is positive with analyst consensus at Buy and a $242.70 price target. Risks include competitive pressures and ongoing legal investigations. Institutional buying and solid cash flow growth underpin the bullish case, though macroeconomic and regulatory factors warrant monitoring.
AT&T (T) trades at $24.48, up 0.2% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 8.2, 16.9% net margin, and consistent dividend payments. Revenue grew to $125.7B in 2025, while debt reduction and fiber expansion with Corning highlight strategic initiatives. Analyst consensus is mixed with 44% buy ratings and a $27.61 price target.
The outlook balances value appeal against competitive pressures. The low valuation and 4% yield attract income investors, but legacy revenue declines and high debt pose risks. Fiber investments and wireless growth offer upside, yet execution and market saturation remain challenges. The stock presents a dividend-income opportunity with moderate growth potential in a competitive telecom landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
